Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO - Concepedia

Concepedia

Publication | Open Access

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO

DOI Full Paper Access

104

Citations

10

References

2018

Year

Chiara Cremolini, Carlotta Antoniotti, Sara Lonardi, Francesca Bergamo, Enrico Cortesi, Giovanni Tomasello, Roberto Moretto, Monica Ronzoni, Patrizia Racca, Fotios Loupakis,

Annals of Oncology

References

	Year	Citations

Page 1